Molecular pathobiology of gastrointestinal stromal sarcomas

Research output: Contribution to journalArticle

245 Citations (Scopus)

Abstract

Gastrointestinal stromal tumors (GISTs) form an interesting group of sarcomas whose unique pathobiology provides a model of how molecularly targeted therapeutics can have a major impact on patient welfare. Approximately 85% of GISTs are driven by oncogenic mutations in either of two receptor tyrosine kinases: KIT or platelet-derived growth factor receptor α. We review the pivotal relationship between specific mutations in these kinase genes, the origin and pathologic spectrum of GISTs, and the response of these tumors to treatment with kinase inhibitors such as imatinib and sunitinib. Mechanisms of resistance to kinase inhibitor therapy are discussed, and targets for the next generation of therapeutics are considered. The rapid evolution in our understanding of GISTs, which stems directly from the close alliance of basic and clinical researchers in the field, illustrates the growing role of the molecular classification of solid tumors in the development of modern oncological treatments.

Original languageEnglish (US)
Pages (from-to)557-586
Number of pages30
JournalAnnual Review of Pathology: Mechanisms of Disease
Volume3
DOIs
StatePublished - 2008

Fingerprint

Gastrointestinal Stromal Tumors
Phosphotransferases
Therapeutics
Platelet-Derived Growth Factor Receptors
Mutation
Receptor Protein-Tyrosine Kinases
Sarcoma
Neoplasms
Research Personnel
Genes

Keywords

  • Gist
  • Imatinib
  • Sunitinib
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

@article{6f654e184cc047249ffcd6b801d06baa,
title = "Molecular pathobiology of gastrointestinal stromal sarcomas",
abstract = "Gastrointestinal stromal tumors (GISTs) form an interesting group of sarcomas whose unique pathobiology provides a model of how molecularly targeted therapeutics can have a major impact on patient welfare. Approximately 85{\%} of GISTs are driven by oncogenic mutations in either of two receptor tyrosine kinases: KIT or platelet-derived growth factor receptor α. We review the pivotal relationship between specific mutations in these kinase genes, the origin and pathologic spectrum of GISTs, and the response of these tumors to treatment with kinase inhibitors such as imatinib and sunitinib. Mechanisms of resistance to kinase inhibitor therapy are discussed, and targets for the next generation of therapeutics are considered. The rapid evolution in our understanding of GISTs, which stems directly from the close alliance of basic and clinical researchers in the field, illustrates the growing role of the molecular classification of solid tumors in the development of modern oncological treatments.",
keywords = "Gist, Imatinib, Sunitinib, Tyrosine kinase inhibitor",
author = "Christopher Corless and Michael Heinrich",
year = "2008",
doi = "10.1146/annurev.pathmechdis.3.121806.151538",
language = "English (US)",
volume = "3",
pages = "557--586",
journal = "Annual Review of Phytopathology",
issn = "1553-4006",
publisher = "Annual Reviews Inc.",

}

TY - JOUR

T1 - Molecular pathobiology of gastrointestinal stromal sarcomas

AU - Corless, Christopher

AU - Heinrich, Michael

PY - 2008

Y1 - 2008

N2 - Gastrointestinal stromal tumors (GISTs) form an interesting group of sarcomas whose unique pathobiology provides a model of how molecularly targeted therapeutics can have a major impact on patient welfare. Approximately 85% of GISTs are driven by oncogenic mutations in either of two receptor tyrosine kinases: KIT or platelet-derived growth factor receptor α. We review the pivotal relationship between specific mutations in these kinase genes, the origin and pathologic spectrum of GISTs, and the response of these tumors to treatment with kinase inhibitors such as imatinib and sunitinib. Mechanisms of resistance to kinase inhibitor therapy are discussed, and targets for the next generation of therapeutics are considered. The rapid evolution in our understanding of GISTs, which stems directly from the close alliance of basic and clinical researchers in the field, illustrates the growing role of the molecular classification of solid tumors in the development of modern oncological treatments.

AB - Gastrointestinal stromal tumors (GISTs) form an interesting group of sarcomas whose unique pathobiology provides a model of how molecularly targeted therapeutics can have a major impact on patient welfare. Approximately 85% of GISTs are driven by oncogenic mutations in either of two receptor tyrosine kinases: KIT or platelet-derived growth factor receptor α. We review the pivotal relationship between specific mutations in these kinase genes, the origin and pathologic spectrum of GISTs, and the response of these tumors to treatment with kinase inhibitors such as imatinib and sunitinib. Mechanisms of resistance to kinase inhibitor therapy are discussed, and targets for the next generation of therapeutics are considered. The rapid evolution in our understanding of GISTs, which stems directly from the close alliance of basic and clinical researchers in the field, illustrates the growing role of the molecular classification of solid tumors in the development of modern oncological treatments.

KW - Gist

KW - Imatinib

KW - Sunitinib

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=41749118496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41749118496&partnerID=8YFLogxK

U2 - 10.1146/annurev.pathmechdis.3.121806.151538

DO - 10.1146/annurev.pathmechdis.3.121806.151538

M3 - Article

C2 - 18039140

AN - SCOPUS:41749118496

VL - 3

SP - 557

EP - 586

JO - Annual Review of Phytopathology

JF - Annual Review of Phytopathology

SN - 1553-4006

ER -